Navigation Links
New DNA and RNA aptamers offer unique therapeutic advantages
Date:8/5/2009

New Rochelle, NY, August 5, 2009A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases, as described in a comprehensive review article published online ahead of print in Oligonucleotides, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/oli

Aptamers offer several advantages compared to protein or small molecule drugs, most notably their ease of production, low risk of inducing an immune reaction in humans, and amenability to chemical modifications that enhance their drug-like properties, including improved stability and residence time in the bloodstream. Aptamer therapeutics presently in clinical development target diseases and applications such as macular degeneration, coronary artery bypass graft surgery, and various types of cancer.

Kristina W. Thiel, PhD and Paloma H. Giangrande, PhD, from the University of Iowa, present a thorough review of aptamers and aptamer-based therapeutic strategies that have the highest likelihood of success. In the article entitled "Therapeutic Applications of DNA and RNA Aptamers," the authors describe the methods used to identify aptamers that specifically bind protein drug targets of interest, the types of modifications that have been made to aptamers to enhance their therapeutic potential, and the different types of aptamers that are currently in development. They also discuss the challenges that must still be overcome for aptamer technology to achieve its full potential.

"This is a comprehensive and timely review of aptamer development and therapeutic applications that our readers should enjoy," says John Rossi, PhD, Co-Editor-in-Chief of Oligonucleotides and Professor in the Department of Molecular Biology, Beckman Research Institute of the City of Hope (Duarte, CA).


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers
2. New lab test offers better prediction of HIV microbicide safety
3. Biological warfare in bacteria offers hope for new antibiotics
4. MS study offers theory for why repair of brains wiring fails
5. M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers
6. Embryology study offers clues to birth defects
7. Stem cell protein offers a new cancer target
8. Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products
9. ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor
10. Novel vaccine approach offers hope in fight against HIV
11. MIT’s implantable device offers continuous cancer monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/30/2019)... ... December 30, 2019 , ... It’s been quite a ... seen its highest sales in 2019, having hosted a multitude of team-building events and ... visited the company’s La Jolla-based venue, and the company has worked hard to accommodate ...
(Date:12/18/2019)... ... December 17, 2019 , ... PM360, a ... and diagnostics industries, has named Pharmafusion LLC as one of the most innovative ... company and its founder/CEO Jonathan Retano. Earlier in the year, Pharmafusion was featured ...
(Date:12/4/2019)... ... December 03, 2019 , ... Genedata, ... Agenus , a clinical-stage immuno-oncology company developing therapies to fight cancer, has ... platform. Agenus will use the platform to support immunotherapy and vaccine pipeline programs ...
Breaking Biology News(10 mins):
(Date:12/18/2019)... ... ... Tune in to CNBC on Saturday, December 28th at 11:00aET to watch a ... on this program. , With a look at Avatar Partners , Advancements will ... the efficiency, safety and effectiveness of equipment, systems, and processes for the Warfighter, First ...
(Date:12/6/2019)... (PRWEB) , ... December 06, ... ... manufacturer Vascular Medcure, Inc. has received FDA 510(k) clearance for its latest ... company’s early clinical data suggests the CAPERE® offers great benefits for first-in-line ...
(Date:12/4/2019)... ... 03, 2019 , ... Absolute Antibody Ltd. , an ... the Recombinant Antibody Network (RAN), a consortium of three expert centers at the ... common goal to generate recombinant antibodies at a proteome-wide scale. Under the new ...
(Date:12/4/2019)... ... , ... A new study released today in STEM CELLS outlines how fat ... tissue) buildup – also improves the range of motion of the affected limb. The ... , The tumor-destroying capabilities of radiation therapy can be a life saver for ...
Breaking Biology Technology: